COVIran Barakat

Last updated
COVIran Barakat
COVIran Barakat.jpg
Vaccine description
Target SARS-CoV-2
Vaccine type Inactivated
Clinical data
Other namesCOVIRAN
Routes of
administration 		Intramuscular
ATC code
  • None
Legal status
Legal status
  • Emergency use authorization: IRN
Full and Emergency Authorizations: List of COVIran Barakat COVID-19 vaccine authorizations

COVIran Barakat is a COVID-19 vaccine developed by Iranian state-owned Shifa Pharmed Industrial Group. It has successfully been tested on animals and has been approved by the Iran Food and Drug Administration for testing on humans. [1] [2] [3] Phase 2/3 (II/III) clinical trial began on 13 March 2021, [4] and the first participants were inoculated on March 29. [5] Finally, the vaccine consumption license was issued on June 13, 2021. [6] Around 650 people worked in 3 shifts around the clock to develop the vaccine. [7]

Contents

According to the production project manager of "CovIran Barakat vaccine", this vaccine—in the second phase—had an immunization of over 93%. According to "Hamidreza Jamshidi" head of the Barakat Pharmaceutical Group, injecting this vaccine raises 93.8% of the neutralizing antibody, which is a specific antibody to Corona. [8] [9] Dr. Minoo Mohraz has been selected as the lead of the "Corona vaccine project in Iran". [10] Dr. Mohraz is an Iranian physician, scientist, and AIDS specialist. She is a Full Professor (Emeritus) of Infectious Diseases at Tehran University of Medical Sciences and head of the Iranian Centre for HIV/AIDS. [11] Dr. Mohraz has also served as within the World Health Organization as an expert on HIV/AIDS in Iran and the Eastern Mediterranean. [12]

This vaccine has been authorised for emergency use by the Iranian authorities. This makes it the first locally developed to be approved for emergency use in the Middle East. [13]

There are claims of some issues with the vaccine's scentific documentation article according to the U.S. Agency for Global Media-owned broadcasting network Radio Farda, [14] which is a U.S. government-funded broadcasting service which aims to provide "objective and accurate news and information to counter state censorship and ideology-based media coverage". [15]

Manufacturing

COVIran Barakat VACCINE.jpg

The mechanism of production of this vaccine is based on the inactivated vaccine. In other words, "it is made of a coronavirus that has been weakened or killed by chemicals, similar to how polio immunizations are made." [16]

According to Setad (the Executive Headquarters of Imam's Directive), under the direct control of the Supreme Leader of Iran, "production of the vaccine developed by one of its companies, Shifa Pharmed, could reach 12 million doses per month, six months after a successful trial ends". [17] On 15 March 2021, he stated that EIKO has already a capacity of three million doses per month and that by end of June the capacity will be 15-20 million doses per month. [18] [19]

On 29 March 2021, the Tehran Times reported that a capacity of three million doses per month was achieved;[ citation needed ] and the production line of 25 million doses per month of Iran Koo vaccine was discharged on 26 April 2021. [20]

On 10 May 2021, the first product of mass production of the Iranian corona vaccine called "COVIran Barakat" was unveiled in phase one of the vaccine production factory associated with Execution of Imam Khomeini's Order (EIKO). Therefore, 2 industrial lines have been set up. The first production line is prepared and the second line is being prepared. By the end of September (taking into account the capacity of three million doses of the first line), 20 million doses of Iran Barakat vaccine will be available in the month. [21]

History

Iran's first domestic COVID-19 vaccine candidate was started Coviran barakat vaccine.jpg
Iran's first domestic COVID-19 vaccine candidate was started
Injection of COVIran Barakat (vaccine); to the Supreme Leader of Iran, Seyyed Ali Khamenei Seyed Ali Khamenei (Iran's supreme leader) injects COVIran Barakat.jpg
Injection of COVIran Barakat (vaccine); to the Supreme Leader of Iran, Seyyed Ali Khamenei

On 29 December 2020, human trials of Iran's first domestic COVID-19 vaccine candidate were started. [16]

Tayyebeh Mokhber, the first volunteer who receives a shot of COVIran Barakat was the daughter of Mohammad Mokhber director of Setad. Minister of Health Saeed Namaki and Vice President for Science and Technology Sorena Sattari participated at the ceremony of vaccine injection. According to reports, there are more than 65,000 Iranians volunteered to test the vaccine and 56 selected people took part in the first phase of human trials which last 45 to 60 days. [22] The initial phase of human-testing for this vaccine started with the injection of 56 volunteers who were at the age of 18–50. [23] [24] [25]

The second/third group of volunteers were also injected with the vaccine. [26] [27] According to the head of the vaccine production team at the Setad, the results show that this vaccine also neutralizes the British mutated COVID-19 virus. [28] [29] [30]

In March 2021, the Executive Office of Imam Khomeini's Order began a Phase II–III clinical trial of COVIran Barakat with 280 participants in cities including Tehran, Mashhad, Karaj, Esfahan, Shiraz. According to the allowance of medical equipment department, the second phase coincided with third phase. [31] [32] The vaccine has reached its third phase of human-testing; [33] and the first injection(s) of the 3rd phase began 25 April 2021. [34]

As official in charge of manufacturing Iran Barakat vaccines, Mohammad Reza Salehi said, “some neighboring countries tend to enter the third phase of the clinical trial of the Iranian "COVIran Barakat"”. They are reviewing recommendations to let them participate. [23]

Authorizations

  Full authorization
  Emergency authorization

See also

Related Research Articles

Sinovac Biotech Ltd. is a Chinese biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. The company is based in Haidian District, Beijing. The company is listed on the NASDAQ but the exchange halted Sinovac's trading in February 2019 due to a proxy fight.

Execution of Imam Khomeinis Order

The Execution of Imam Khomeini's Order (EIKO),, also known as the Executive Headquarters of Imam's Directive or simply Setad, is a parastatal in the Islamic Republic of Iran, under direct control of the Supreme Leader of Iran. It was created from thousands of properties confiscated in the aftermath of the 1979 Islamic Revolution. A Reuters investigation found that the organization built "its empire on the systematic seizure of thousands of properties belonging to ordinary Iranians", also seizing property from members of religious minorities, business people and Iranians living abroad; at times falsely claiming that the properties were abandoned.

Barakat Foundation

The Barakat Foundation is connected to Execution of Imam Khomeini's Order for the purpose of helping the underprivileged. According to Reuters, the foundation "is a unit of a massive business empire controlled by Seyyed Ali Khamenei that is known as Setad Ejraiye Farmane Hazrate Emam," which has become one of the most powerful Iranian institutions through the seizure of properties belonging to Iranian citizens.

Barakat Pharmaceutical Group

Barkat Pharmaceutical Group is an Iranian Pharmaceutical public company, which was founded in 2010, named Tadbir innovation pharmaceutical company. The company provides services through cooperation between science-based institutions and scientists based on medicine around the world. It supplies 14 percent of all the country's essential drugs through its 25 subsidiaries. The company produces 700 kinds of products in the pharmaceutical sector and offers it internally. The Barkat Pharmaceutical Group has established as the first specialized drug and pharmaceutical research center in Iran, also it has been developed by constructing advanced pharmaceutical factories, called Barkat Pharmaceutical Town. The Barkat group complies with all common pharmaceutical standards such as the FDA, WHO, EMEA. "Cell therapy", production of "peptide medications", "research, development and processing of medicinal plants," the creation of the "Museum of Iranian-Islamic Medicine" as well as "Solids and Semi-Solids" projects are the main activities of the Group.

COVID-19 pandemic in Iran Ongoing COVID-19 viral pandemic in Iran

The COVID-19 pandemic in Iran is part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. On 19 February 2020, Iran reported its first confirmed cases of infections in Qom. The virus may have been brought to the country by a merchant from Qom who had travelled to China.

COVID-19 vaccine Designed to provide acquired immunity against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine technologies during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19. The COVID‑19 vaccines are widely credited for their role in reducing the spread, severity, and death caused by COVID-19.

Moderna COVID-19 vaccine RNA COVID-19 vaccine

The Moderna COVID‑19 vaccine, codenamed mRNA-1273 and sold under the brand name Spikevax, is a COVID-19 vaccine developed by Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA). It is authorized for use in people aged 12 years and older in some jurisdictions and for people 18 years and older in other jurisdictions to provide protection against COVID-19 which is caused by infection by the SARS-CoV-2 virus. It is designed to be administered as two 0.5 mL doses given by intramuscular injection at an interval of 29 days apart.

Convidecia Vaccine against COVID-19

AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics. It conducted its Phase III trials in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants.

Oxford–AstraZeneca COVID-19 vaccine Vaccine against COVID-19

The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed by Oxford University and AstraZeneca, it is given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. Another analysis showed that, for symptomatic COVID-19 infection after the second dose, the vaccine is 66% effective against the Alpha variant, and 60% against the Delta variant.

CoronaVac Vaccine against COVID-19

CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was Phase III clinical trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to BBIBP-CorV and Covaxin, other inactivated-virus COVID-19 vaccines. CoronaVac does not need to be frozen and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept.

Barkat Ventures is an Iranian knowledge-based institute which has been established as the arm of the Imam (Khomeini)'s Command's Executive in order to develop knowledge-based economy. This institute's mission is to create and expand on the ecosystem/infrastructure for the development of science and knowledge-based activities of the scholars in Iran on the basis of Islamic-Iranian models by utilizing Iranian scientists, experts, global-experience, knowledge and so on.

Novavax COVID-19 vaccine Vaccine candidate against COVID-19

The Novavax COVID-19 vaccine, codenamed NVX-CoV2373, is a subunit COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI), that is undergoing trials in India under the brand name Covovax. It requires two doses and is stable at 2 to 8 °C refrigerated temperatures.

COVID-19 vaccination in India Immunisation programme against COVID-19 in India

India began administration of COVID-19 vaccines on 16 January 2021. As of 25 July 2021, India has administered over 435 million doses overall, including first and second doses of the currently-approved vaccines.

History of COVID-19 vaccine development Scientific work to develop a vaccine for COVID-19

COVID-19's caused virus, SARS-CoV-2, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

Soberana 02 Vaccine against COVID-19

Soberana 02 or Soberana 2, technical name FINLAY-FR-2, is a COVID-19 vaccine produced by the Finlay Institute, a Cuban epidemiological research institute. It is a conjugate vaccine. This candidate followed a previous one called SOBERANA-01 (FINLAY-FR-1). Professor Ihosvany Castellanos Santos said that the antigen is safe because it contains parts instead of the whole live virus, and therefore it does not require extra refrigeration, like other candidates in the world. According to the WHO candidate landscape vaccine document, this vaccine requires two doses, the second one being administered 28 days after the first shot.

EpiVacCorona EpiVacCorona vaccine against COVID-19

EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the VECTOR center of Virology. It consists of three chemically synthesized peptides that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. The third phase of a clinical trial, which should show whether the vaccine is able to protect people from COVID-19 or not, was launched in November 2020 with more than three thousand participants. It is assumed it will be completed in August 2021. According to the vaccine developers, the peptides and the viral part of the chimeric protein should immunize people who received this vaccine against SARS-CoV-2 and trigger the production of protective antibodies. However, some experts in the field have expressed concerns about the selection of peptides for use as vaccine antigens. In addition, there are also serious concerns about the vaccine immunogenicity data, which have fueled independent civic research efforts and criticism by some experts. Meanwhile, the EpiVacCorona has received vaccine emergency authorization in a form of government registration in Russia and is available for vaccination outside the clinical trials. The vaccine delivered via intramuscular route and aluminum hydroxide serves as an immunological adjuvant.

COVID-19 vaccination in South Africa Plan to immunize against COVID-19 in South Africa

COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

ZyCoV-D Vaccine candidate against COVID-19

ZyCoV-D is a DNA plasmid based COVID-19 vaccine being developed by Cadila Healthcare with support from the Biotechnology Industry Research Assistance Council.

Nanocovax Vaccine candidate against COVID-19

Nanocovax is a Vietnamese COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC. It is a subunit vaccine.

References

  1. ↑ Bulos N (19 January 2021). "Iranians demand a COVID-19 vaccine, not politics, from their leaders". Los Angeles Times . Archived from the original on 2021-01-19.
  2. ↑ Khoshhal P (21 January 2021). "Coronavirus Tzar Forced to Apologize to Clergy". iranwire. Archived from the original on 2021-01-21.
  3. ↑ Vahdat A (29 December 2020). "Iran begins human trials for locally made coronavirus vaccine". Times of Israel. Archived from the original on 16 January 2021. Retrieved 30 December 2020.
  4. ↑ "IRCT | A double-blind, randomized, placebo-controlled Phase II/III Clinical trial to evaluate the safety and efficacy of COVID-19 inactivated vaccine (Shifa-Pharmed) in a population aged 18 to 75 years". en.irct.ir. Iranian Registry of Clinical Trials (IRCT). Archived from the original on 2021-04-23. Retrieved 2021-04-07.
  5. ↑ 3080 (30 March 2021). "Some foreign states willing to cooperate in COVIran Barakat clinical test: Official". Islamic Republic News Agency English. Archived from the original on 2021-03-31. Retrieved 2021-04-07.CS1 maint: numeric names: authors list (link)
  6. ↑ "مجوز مصرف واکسن "کووایران برکت" صادر شد" [The license to use the "Kovairan Barakat" vaccine was issued]. Young Journalists Club (in Persian). Archived from the original on 26 June 2021. Retrieved 16 June 2021.
  7. ↑ "دانش فنی واکسن برکت صد درصد ایرانی است/ تلاش ۶۵۰ نفر در ساخت واکسن ایرانی کرونا" [Vaccine technical knowledge is 100% Iranian / 650 people participated in developing Iranian COVID-19 vaccine]. Tasnim News Agency (in Persian). Archived from the original on 9 July 2021. Retrieved 2021-06-26.
  8. ↑ "توانایی تامین واکسن مورد نیاز کشور را تا پایان پاییز داریم" [We have the ability to supply the vaccine needed by the country until the end of autumn]. Mehr News (in Persian). Retrieved 3 July 2021.
  9. ↑ "ایمنی‌زایی ۹۳.۵درصدی واکسن برکت در فاز دوم/ ۱۲ کشور برای خرید درخواست دادند" [93.5% immunity for Barakat vaccine in Phase II / 12 countries apply for purchase]. Tasnim News Agency (in Persian). Retrieved 24 June 2021.
  10. ↑ Ardalan S (6 December 2020). "واکسن ایرانی کرونا تا 'تیر ماه آینده می‌رسد'" [Iranian corona vaccine will arrive by 'next July']. BBC News (in Persian). Archived from the original on 2020-12-06. Retrieved 2020-12-18.
  11. ↑ "Good News About AIDS". Young Journalists Club. February 6, 2016. Retrieved 2020-02-26.
  12. ↑ "علامه طباطبایی استاد مينو محرز: هرچه دارم از دانشگاه علوم پزشكي تهران است" [Allameh Tabatabai | Professor Minoo Mehrz: Everything I have is from Tehran University of Medical Sciences] (in Persian). Tehran University of Medical Sciences Alumni Communication Office. Archived from the original on May 19, 2021. Retrieved March 29, 2017.
  13. ↑ Baghishov E (14 June 2021). "Iran issues license on its coronavirus vaccine". Trend.Az. Archived from the original on 2021-06-14. Retrieved 14 June 2021.
  14. ↑ "خامنه‌ای پس از دریافت "واکسن ایرانی کرونا": واکسن خارجی هم ایرادی ندارد" [Khamenei after receiving the "Iranian corona vaccine": There is no problem with the foreign vaccine]. رادیو فردا (in Persian). Archived from the original on 2021-06-26. Retrieved 2021-06-26.
  15. ↑ "About Us". RadioFreeEurope. Retrieved 13 July 2021.
  16. 1 2 "Iran begins first human trial of locally made virus vaccine". health.economictimes.indiatimes. 29 December 2019. Archived from the original on 3 February 2021.
  17. ↑ "Iran starts human testing of first domestic COVID-19 vaccine". reuters. 29 December 2019. Archived from the original on 12 January 2021.
  18. ↑ "Iran starts mass-production of homegrown coronavirus vaccine". Tehran Times. 2021-03-15. Archived from the original on 2021-03-22. Retrieved 2021-04-07.
  19. ↑ "Iran to kick off production of 3mn doses of COVIRAN". Mehr News Agency. 2021-03-15. Archived from the original on 2021-03-15. Retrieved 2021-04-07.
  20. ↑ "خط تولید ۲۵ میلیون دوز در ماه واکسن کوو ایران برکت ترخیص" [The production line of 25 million doses per month of Iran Koo vaccine was cleared]. Tasnim News Agency (in Persian). Archived from the original on 26 June 2021.
  21. ↑ "نخستین محصول تولید انبوه واکسن "کوو ایران برکت" فردا رونمایی می‌شود" [The first mass-produced product of "Koo Iran Barakat" vaccine will be unveiled tomorrow]. irna (in Persian). 10 May 2021. Archived from the original on 17 May 2021. Retrieved 26 June 2021.
  22. ↑ Motamedi M (29 December 2020). "COVIran Barakat: Iran launches human trials of its COVID vaccine". Al Jazeera. Archived from the original on 31 January 2021.
  23. 1 2 "Some foreign states willing to cooperate in COVIran Barakat clinical test: Official". irna. 30 March 2021. Archived from the original on 2021-03-31. Retrieved 2021-04-07.
  24. ↑ "تست انسانی واکسن ایرانی کرونا آغاز شد/ وزیر بهداشت: ما با ۱۰۰ سال سابقه، اولین واکسن‌ساز آسیا هستیم" [Human test of Iranian corona vaccine begins / Minister of Health: We are the first vaccinator in Asia with 100 years of experience]. Tasnim News Agency (in Persian). Archived from the original on 26 June 2021.
  25. ↑ "پایان تزریق فاز یک مطالعات واکسن کووایران برکت" [End of the injection of phase one (studies) of "Kovoo-Iran Barakat" vaccine]. Young Journalists Club (in Persian). Archived from the original on 14 July 2021. Retrieved 16 February 2021.
  26. ↑ "آغاز تزریق واکسن ایرانی کرونا به دومین گروه از داوطلبان" [Start of injecting the Iranian corona vaccine to the second group of volunteers]. Mehr News Agency (in Persian). Archived from the original on 26 June 2011.
  27. ↑ "تزریق "واکسن ایرانی کرونا" به دومین گروه از داوطلبان آغاز شد" [The injection of "Iranian corona vaccine" to the second group of volunteers began]. Tasnim News Agency (in Persian). Archived from the original on 26 June 2016.
  28. ↑ "جلیلی: واکسن کوو ایران برکت، ویروس انگلیسی را خنثی می‌کند" [Jalili: The Iranian vaccine neutralizes the British virus]. Young Journalists Club (in Persian). Archived from the original on 26 June 2021.
  29. ↑ "موفقیت واکسن ایرانی در خنثی کردن "ویروس جهش‌یافته انگلیسی"" [Iranian vaccine succeeds in neutralizing "British mutated virus]. Iranian Students News Agency (in Persian). Archived from the original on 26 June 2021.
  30. ↑ Haghdoost H (17 February 2021). "Iran Vaccine Boasts Total Protection Against U.K. Covid Strain". bloomberg. Archived from the original on 2021-04-15. Retrieved 2021-04-08.
  31. ↑ "Clinical trials of COVIRAN vaccine enter phases 2, 3". Iranian Students News Agency. 15 March 2021. Archived from the original on 11 May 2021. Retrieved 8 April 2021.
  32. ↑ "واکسن ایران برکت احتمالا تا پایان خرداد ۱۴۰۰ به دست هموطنان می‌رسد" [Iran Barakat vaccine will probably reach our compatriots by the end of June 1400]. Iranian Students News Agency (in Persian). 24 March 2021. Archived from the original on 26 June 2021.
  33. ↑ "آغاز مرحله سوم تست انسانی کووایران برکت" [The beginning of the third stage of the human test of COVIran Barakat]. Islamic Republic of Iran News Network (in Persian). Archived from the original on 2021-06-26. Retrieved 21 April 2021.
  34. ↑ "تزریق فاز سوم واکسن کوو ایران برکت انجام شد" [The third phase of Iran Barakat vaccine was injected]. Young Journalists Club (in Persian). Archived from the original on 26 June 2021. Retrieved 25 April 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.